Compare Moderna, Inc. (MRNA) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Paychex, Inc. — how do they compare? Moderna, Inc. trades at $59.72 (market cap $23.60B), while Paychex, Inc. trades at $115.19 (market cap $40.98B). The key difference: Paychex, Inc. is the larger of the two by market cap, and Paychex, Inc. pays a 4.13% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | PAYX | |
|---|---|---|
Market Cap | $23.60B | $40.98B |
Sector | Health | Industrials |
52-Week High | $81.80 | $147.99 |
52-Week Low | $22.36 | $85.57 |
Enterprise Value | $19.70B | $44.47B |
Dividend Yield | — | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
Paychex (PAYX) trades at $111.96, down 2.12% on the day, with technical indicators showing a bullish trend despite overbought RSI readings. The company maintains strong profitability with 27.03% net margins and has beaten earnings estimates for three consecutive quarters. Recent dividend declarations of $1.19 per share and positive small business job growth data support the investment case.
The outlook remains positive with steady revenue growth and AI expansion driving future earnings. Key risks include macroeconomic headwinds affecting small business hiring and elevated valuation multiples. Analyst consensus is mixed with a $110 price target slightly below current levels, suggesting cautious optimism amid strong fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
